After parathyroidectomy, morbidity and mortality rates were considerably higher in patients with secondary and tertiary vs primary hyperparathyroidism.
Data were collected from the Nurses' Health Study I to examine the relationship between BMI and primary hyperparathyroidism risk.
The drug's approval was based on 2 successful phase 3 trials.
Etelcalcetide shows promise for reducing parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism.
Study reveals 6-fold higher risk of secondary hyperparathyroidism in patients on furosemide vs hydrochlorothiazide.
Quality-of-life scores improved significantly after successful parathyroidectomy.
Reduced fracture risk for surgery; bisphosphonate treatment no better than observation
Recent data showed that parathyroidectomy is more effective for controlling hypercalcemia after kidney transplants in patients with persistent hyperparathyroidism.
The correlation persists regardless of concurrent oral bisphosphonate administration.
More patients with abnormal bone mineral density should undergo screening for primary hyperparathyroidism.
AMG 416 demonstrated positive results for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.
Endocrinology Advisor Articles
- Effect of Sugar-Sweetened Beverages on Obesity Development
- Metformin and PCOS: Improving Menstrual Cycle and Hormone Profiles
- Denosumab May Increase BMD in Women With Primary Hyperparathyroidism
- T2D May Play a Protective Role Against Developing Aortic Diseases
- Risk Factors for Diabetes May Be Identified 20 Years Before Diagnosis
- Metformin Safe in T2D With Moderate to Severe Chronic Kidney Disease
- SGLT2 Inhibitors Show High Cardiovascular- and Renal-Protective Effects in T2D
- Type 2 Diabetes Insulin Initiation: Predictors Identified
- Two New Diabetes Medications Now Available
- Managing Acute Pain in Patients With Severe Obesity
- Risk for Congenital Malformations With Antithyroid Drugs
- Occupational Therapy May Benefit Young Adults With Diabetes
- Weight Loss May Improve Pain in Patients With Obesity
- Prior Authorizations Are Creating a Challenge for Clinicians
- Effect of Biologic DMARDs on Spinal Fracture Risk in Ankylosing Spondylitis